Cypherpunk Technologies reported a $37.8 million loss in the first half of 2026 despite holding 323,394 ZEC valued at about $157 million, more than double its $74 million market cap. The company is pivoting to fund Phase 3 trials for its cancer drug Sirexatamab, which failed to show benefits in Phase 2 but received FDA fast track status. With only $7.6 million in cash and ongoing losses, Cypherpunk faces a tough financial path, balancing its crypto asset accumulation goal with costly drug development. The company is seeking external funding options but has not secured any partnerships yet, raising investor concerns about its future.
Industrial Alliance Securities lowered Abeona Therapeutics' price target from $20 to $15 following a 14% stock drop after the company reported Q2 revenues of $11.4 million, missing analyst expectations. The company faces operational challenges with i...
Inovio Pharmaceuticals is progressing its DNA medicine pipeline with its lead candidate INO-3107 for Recurrent Respiratory Papillomatosis under FDA accelerated review, targeting a decision by October 30, 2026. The company raised $18.3 million in fund...
Morin Brit, a director at Life360, sold 15,582 shares of the company, generating $1 million from the transaction. This sale may indicate a personal financial decision or portfolio adjustment by the director. Investors might watch for any further insi...
AbCellera Biologics announced positive Phase 2 trial results for its experimental menopause drug ABCL635, which significantly reduced hot flash frequency by 83%. The stock surged 33.19% to a 52-week high of $11.32, boosting the company's market cap t...
TOMI Environmental Solutions reported a 118% year-over-year revenue increase to $2.25 million, surpassing analyst estimates of $1.84 million. The company also beat EPS expectations with a loss of $0.05 per share, better than the anticipated loss of $...
